Adrenergic and muscarinic receptor mapping explains bronchodilators, beta blockers, atropine, cholinesterase inhibitors and cholinergic poisoning.
Bronchodilatation can be achieved either by stimulating beta-2 receptors or by blocking muscarinic receptors.
Today’s single episode uses receptor location to make autonomic pharmacology clinically understandable. The sympathetic nervous system supports the fight-or-flight response through adrenaline and noradrenaline acting at alpha and beta receptors. Alpha-1 stimulation causes vasoconstriction and pupil dilatation, while beta-1 stimulation increases heart rate and contractility. Beta-2 stimulation relaxes bronchial smooth muscle, explaining the bronchodilator effect of medicines such as salbutamol and salmeterol.
The same receptor map helps predict adverse effects. A beta-2 agonist is intended to open the airways, but systemic exposure can also produce tremor and tachycardia. Beta-1 antagonists reduce heart rate and contractility, supporting their use in conditions such as hypertension and angina. Alpha-2 agonism reduces sympathetic outflow through presynaptic inhibition, which explains the different physiological effect of clonidine despite it still acting within the adrenergic system.
Parasympathetic pharmacology is organised around acetylcholine and muscarinic receptors. M2 activity slows the heart, while M3 activity contributes to bronchial constriction, secretions, gastrointestinal motility, bladder emptying and pupil constriction. Blocking cardiac muscarinic effects with atropine can therefore increase heart rate during significant bradycardia. Blocking muscarinic activity in the airways with ipratropium or tiotropium supports bronchodilatation through a different mechanism from beta-2 agonists.
The episode also shows how drug effects can be increased without directly stimulating a receptor. Cholinesterase inhibitors reduce acetylcholine breakdown, leaving more neurotransmitter available at the synapse. Neostigmine can increase acetylcholine at the neuromuscular junction in myasthenia gravis or during reversal of non-depolarising neuromuscular blockade. Donepezil similarly increases central acetylcholine availability in Alzheimer’s disease, although it does not reverse the underlying neurodegenerative process.
Organophosphate exposure demonstrates the clinical consequences of excessive cholinergic activity. Miosis, bronchoconstriction, bradycardia, diarrhoea, urination, vomiting, lacrimation and salivation reflect widespread acetylcholine effects. Respiratory compromise from bronchial secretions, bronchoconstriction and bradycardia makes early recognition essential. Atropine reduces the dangerous muscarinic effects by blocking acetylcholine at its target receptors.
Emergency, respiratory, toxicology and pharmacology learners get a mechanism-first review of the autonomic nervous system. Adrenergic and muscarinic receptors are linked to clinically familiar drugs including salbutamol, beta blockers, clonidine, atropine, ipratropium, tiotropium, neostigmine and donepezil.
Before giving an autonomic medicine, name the target receptor, the organ involved and the physiological effect you want. Anticipate predictable consequences such as tremor or tachycardia after beta-2 agonists, reduced heart rate after beta blockade and increased secretions or bronchoconstriction during cholinergic excess. In suspected pesticide poisoning, actively look for the wider muscarinic pattern rather than focusing on pupil size alone.
A patient with acute wheeze receives inhaled salbutamol and subsequently develops tremor and tachycardia. Which receptor produces the intended respiratory effect?
Beta-2 receptor stimulation relaxes bronchial smooth muscle and produces bronchodilatation. Tremor and tachycardia can occur when beta-agonist effects extend beyond the intended airway response.
A patient has clinically significant bradycardia caused by excessive parasympathetic slowing of the sinoatrial node. How does atropine increase the heart rate?
Atropine blocks muscarinic acetylcholine receptors, including cardiac M2 effects. This reduces parasympathetic inhibition of the sinoatrial node and allows the heart rate to rise.
A farm worker develops miosis, salivation, vomiting, diarrhoea, bradycardia and bronchial secretions after pesticide exposure. What pharmacological syndrome is present, and what is atropine intended to treat?
The presentation reflects excessive cholinergic activity from suspected organophosphate exposure. Atropine blocks the dangerous muscarinic effects, including bronchial secretions, bronchoconstriction and bradycardia.
.svg)